Affiliations: [a] Research Memory Center University Hospital Lille Nord de France, UDSL, Lille, France | [b] Research Memory Center, Neurology Department and INSERM UMR1079, Rouen University Hospital, Rouen, France | [c] INSERM U942, Paris, France | [d] Department of Histology, Lariboisière Fernand Widal Saint Louis Hospital, APHP, University of Paris Diderot, Paris, France | [e] Institut du Fer à Moulin Inserm UMR S839, Paris, France | [f] Research Memory Center EA COBTEK, University Hospital of Nice Sophia Antipolis, France | [g] Research Memory Center, Lariboisière FW Saint-Louis Hospital, APHP, University of Paris Diderot, Paris, France
Correspondence:
[*]
Correspondence to: Dr. Claire Paquet, Centre Mémoire de Ressources et de Recherche, Groupe Hospitalier Lariboisière FW Saint Louis, 200 rue du Faubourg Saint Denis, 75010 Paris, France. Tel.: +33 149956977; Fax: +33 149958495; E-mail: claire.paquet@inserm.fr.
Note: [1] These authors contributed equally to this work.
Abstract: Cerebrospinal fluid (CSF) biomarkers for Alzheimer's disease (AD) are well validated in clinical research but less in clinical practice. Using a questionnaire, we evaluated the reasons for prescriptions and clinician's expectations concerning CSF biomarkers. The results show that CSF AD biomarkers are mainly required in case of atypical dementia and diagnosis uncertainty that are different from indications in clinical research. In the future, clinicians wish to get new biomarkers that could improve differential diagnosis and could have a good pronostic value. Further studies in routine practice are necessary to precise the role of these biomarkers in the management of patients.
Keywords: Alzheimer's disease, biomarkers, cerebrospinal fluid, clinical practice
